BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Core Points - BriaCell Therapeutics Corp. has been granted New Zealand Patent No. 785587 for its whole-cell cancer immunotherapy technology, which focuses on HLA allele profile matching for personalized treatment [1][2] - The patent provides exclusivity until February 27, 2037, supporting the company's precision medicine approach aimed at improving patient outcomes [1] - The newly granted patent is part of BriaCell's strategy to build a strong international patent portfolio for the global development and commercialization of its immunotherapy platform across various cancer indications [2] Company Overview - BriaCell is a clinical-stage biotechnology company dedicated to developing novel immunotherapies to transform cancer care [3]